US Patent

US10137200 — Surfactant-free water-free foamable compositions, breakable foams and gels and their uses

Method of Use · Assigned to Foamix Pharmaceuticals Ltd · Expires 2030-10-01 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treatment using a composition that includes a tetracycline antibiotic, such as minocycline hydrochloride, without surface active agents.

USPTO Abstract

A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2647 minocycline-hydrochloride

Patent Metadata

Patent number
US10137200
Jurisdiction
US
Classification
Method of Use
Expires
2030-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Foamix Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.